ASH 2019 | Encouraging results for ibrutinib with venetoclax in R/R CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the design and results of the phase II study (NCT02756897) evaluating ibrutinib and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Results show that combined venetoclax and ibrutinib is an effective and well-tolerated regimen for patients with R/R CLL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up